Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)open access
- Authors
- Jung, SH[Jung, Sung-Hoon]; Lee, JJ[Lee, Je-Jung]; Kim, JS[Kim, Jin Seok]; Min, CK[Min, Chang-Ki]; Kim, K[Kim, Kihyun]; Choi, Y[Choi, Yunsuk]; Eom, HS[Eom, Hyeon-Seok]; Joo, YD[Joo, Young Don]; Kim, SH[Kim, Sung-Hyun]; Kwak, JY[Kwak, Jae-Yong]; Kang, HJ[Kang, Hye Jin]; Lee, JH[Lee, Jae Hoon]; Lee, HS[Lee, Ho Sup]; Mun, YC[Mun, Yeung-Chul]; Moon, JH[Moon, Joon Ho]; Sohn, SK[Sohn, Sang Kyun]; Park, SK[Park, Seong Kyu]; Park, Y[Park, Yong]; Shin, HJ[Shin, Ho-Jin]; Yoon, SS[Yoon, Sung-Soo]
- Issue Date
- May-2018
- Publisher
- ELSEVIER SCIENCE INC
- Keywords
- Intravenous busulfan; Melphalan; Multiple myeloma; Autologous transplantation
- Citation
- BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, v.24, no.5, pp.923 - 929
- Indexed
- SCIE
SCOPUS
- Journal Title
- BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Volume
- 24
- Number
- 5
- Start Page
- 923
- End Page
- 929
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/20113
- DOI
- 10.1016/j.bbmt.2018.01.004
- ISSN
- 1083-8791
- Abstract
- This prospective study evaluated the efficacy and toxicity of intravenous busulfan and melphalan as a conditioning regimen for autologous stern cell transplantation (ASCT) in patients with multiple myeloma (MM). A total of 99 patients with MM, enrolled between January 2013 and March 2016, received intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m(2)) before ASCT. The median time to transplant was 6.2 months, and 90 (90.9%) patients underwent ASCT within 12 months of the diagnosis. The overall response rate after ASCT was 94.0%, including 43.5% with a stringent complete response/complete response, 27.3% with very good partial response, and 23.2% with partial response. The most common severe nonhematologic toxicity (grade 3 to 4) was infection (26.3%) and stomatitis (15.2%). Three (3.2%) patients developed veno-occlusive disease. No treatment-related mortality was observed. After a median follow-up of 26.1 months, the median progression free survival was 27.2 months (range, 13.0 to 41.4 months) and median overall survival was not reached. In conclusion, a conditioning regimen of intravenous busulfan and melphalan was effective and tolerable. ClinicalTrials.gov. number: NCT01923935 (C) 2018 American Society for Blood and Marrow Transplantation.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/20113)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.